TY - JOUR
T1 - iPSC-derived neural precursor cells
T2 - potential for cell transplantation therapy in spinal cord injury
AU - Nagoshi, Narihito
AU - Okano, Hideyuki
N1 - Funding Information:
Acknowledgements We appreciate the help of Drs. Masaya Naka-mura, RyoYamaguchi, Munehisa Shinozaki, Keiko Sugai, Kota Kojima, who all members of the spinal cord research team in the Department of Physiology and Orthopaedic Surgery. This work was supported by Research Center Network for Realization of Regenerative Medicine the Japan Agency for Medical Research and Development (AMED) (to H.O.). H.O. is a founding scientist of SanBio Co. Ltd and K Pharma Inc. N.N. has no conflict of interest.
Publisher Copyright:
© 2017, Springer International Publishing AG.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - A number of studies have demonstrated that transplantation of neural precursor cells (NPCs) promotes functional recovery after spinal cord injury (SCI). However, the NPCs had been mostly harvested from embryonic stem cells or fetal tissue, raising the ethical concern. Yamanaka and his colleagues established induced pluripotent stem cells (iPSCs) which could be generated from somatic cells, and this innovative development has made rapid progression in the field of SCI regeneration. We and other groups succeeded in producing NPCs from iPSCs, and demonstrated beneficial effects after transplantation for animal models of SCI. In particular, efficacy of human iPSC–NPCs in non-human primate SCI models fostered momentum of clinical application for SCI patients. At the same time, however, artificial induction methods in iPSC technology created alternative issues including genetic and epigenetic abnormalities, and tumorigenicity after transplantation. To overcome these problems, it is critically important to select origins of somatic cells, use integration-free system during transfection of reprogramming factors, and thoroughly investigate the characteristics of iPSC–NPCs with respect to quality management. Moreover, since most of the previous studies have focused on subacute phase of SCI, establishment of effective NPC transplantation should be evaluated for chronic phase hereafter. Our group is currently preparing clinical-grade human iPSC–NPCs, and will move forward toward clinical study for subacute SCI patients soon in the near future.
AB - A number of studies have demonstrated that transplantation of neural precursor cells (NPCs) promotes functional recovery after spinal cord injury (SCI). However, the NPCs had been mostly harvested from embryonic stem cells or fetal tissue, raising the ethical concern. Yamanaka and his colleagues established induced pluripotent stem cells (iPSCs) which could be generated from somatic cells, and this innovative development has made rapid progression in the field of SCI regeneration. We and other groups succeeded in producing NPCs from iPSCs, and demonstrated beneficial effects after transplantation for animal models of SCI. In particular, efficacy of human iPSC–NPCs in non-human primate SCI models fostered momentum of clinical application for SCI patients. At the same time, however, artificial induction methods in iPSC technology created alternative issues including genetic and epigenetic abnormalities, and tumorigenicity after transplantation. To overcome these problems, it is critically important to select origins of somatic cells, use integration-free system during transfection of reprogramming factors, and thoroughly investigate the characteristics of iPSC–NPCs with respect to quality management. Moreover, since most of the previous studies have focused on subacute phase of SCI, establishment of effective NPC transplantation should be evaluated for chronic phase hereafter. Our group is currently preparing clinical-grade human iPSC–NPCs, and will move forward toward clinical study for subacute SCI patients soon in the near future.
KW - Central nervous system
KW - Mechanisms for functional recovery
KW - Regeneration
KW - Safety issue
KW - Stem cell graft
UR - http://www.scopus.com/inward/record.url?scp=85030865263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030865263&partnerID=8YFLogxK
U2 - 10.1007/s00018-017-2676-9
DO - 10.1007/s00018-017-2676-9
M3 - Review article
C2 - 28993834
AN - SCOPUS:85030865263
VL - 75
SP - 989
EP - 1000
JO - Experientia
JF - Experientia
SN - 1420-682X
IS - 6
ER -